IN VITRO CELL-BASED ASSAYS FOR SCREENING AND COMPARISON OF TNF-Α AND IL-17A INHIBITORS AND THEIR BIOSIMILARS

Abstract

Cell-based bioassays have been developed to assess the biological activity of TNF-α and IL-17A inhibitors based on primary human cell cultures obtained from tissues of juvenile donors. The Fibro-bioassay is based on the analysis of IL-17A dose-dependent production of inflammatory cytokines synthesized by human foreskin fibroblasts (HFF). Using this bioassay, it has been shown that Netakimab (Biocad, RF) is a highly effective inhibitor of IL-17A. Using the Chondro test system the biological activity of TNF-α inhibitors was compared: the original molecule Remicade (MSD, Ireland) with its biosimilar Infliximab (Biocad, Russia).